Octapharma Expects To Have Octagam Back On the Market By Year's End
This article was originally published in The Pink Sheet Daily
Executive Summary
The company withdraws its IVIG Octagam 5% from the U.S. market following increased reports of thromboembolic events; it is challenging EMA's recommendation to withdraw the 10% formulation in Europe.
You may also be interested in...
FTC Taking A Closer Look At Talecris/Grifols Merger; HIGPA Voices Concerns
The Federal Trade Commission has requested further information from both Talecris Biotherapeutics and Grifols in relation to the two companies' proposed merger
Deals Of The Week: Grifols/Talecris, Sanofi/Vivalis, Forest/TransTech ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog; this week's edition wraps up deals from late December. Visit the blog at 1http://invivoblog.blogspot.com/.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.